Ligand Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ligand Pharma (LGND) Tops Q2 EPS by 24c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
August 3, 2020 7:37 AM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.00, $0.24 better than the analyst estimate of $0.76. Revenue for the quarter came in at $41.4 million versus the consensus estimate of $31.39 million.
Outstanding second quarter financial results and operating execution have laid the foundation for our strong outlook for the rest of 2020 and beyond. We... More
